Recent studies have converged on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine communication. While GIP stimulators are increasingly employed for managing type 2 diabetes mellitus, their emerging impacts on motivation circu